Day One Biopharmaceuticals (NASDAQ:DAWN) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $32.00 price objective on the stock. A number of other research analysts have also recently weighed in on the company. Bank of […]
Needham & Company LLC reissued their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $32.00 price objective on the stock. A number of other research analysts have also recently weighed in on the company. Bank of […]
